C. Navarrete
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
C. Navarrete has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
C. Brown
Histocompatibility and Immunogenetics Laboratory, National Health Service Blood and Transplant (NHSBT), Colindale Centre, London, UK
2 shared publicationsS. P. Cardoso
Histocompatibility and Immunogenetics (H&I) laboratory, National Health Service Blood and Transplant (NHSBT), Colindale Centre, London, UK
2 shared publications- Anthony Richard Green
Cambridge Stem Cell Institute, Department of Haematology, University of Cambridge, Cambridge, United Kingdom
1 shared publication D. Railton
NBS‐North London Centre
1 shared publicationG. Lucas
H&I laboratory NHSBT Filton, Bristol UK
1 shared publicationGeoff Lucas
1 shared publication
Latest Publications
- 9 February 2013
- Published by Wiley in Vox Sanguinis
- Vol. 105 (1) , 65-72
Determination of human neutrophil antigen‐1, ‐3, ‐4 and ‐5 allele frequencies in English Caucasoid blood donors using a multiplex fluorescent DNA‐based assay
Background and Objectives A number of DNA‐based methods to genotype the alleles coding for HNA have been described, but all require the separate amplification and analysis of each allele. The aim was to develop a DNA‐based method for simultaneous detection of HNA‐1, HNA‐3, HNA‐4 and HNA‐5 alleles. Materials and Methods An allele‐specific primer extension method was used in combination with magnetic beads from Luminex technology. PCR–sequence‐specific primers (SSP) was used to resolve the presence of the HNA‐1b allele in samples assigned by the Luminex bead assay as HNA‐1a/‐1b/‐1c or HNA‐1b/‐1c. HNA allele frequencies were determined in a panel of 140 randomly selected English Caucasoid blood donors. Results HNA allelic types were compared with historical results, and 100% concordance was found. Only eight of the 97 samples used in the validation required additional testing by PCR–SSP. Allele frequencies were determined in the blood donor population as follows: 0·318 for HNA‐1a, 0·668 for HNA‐1b, 0·014 for HNA‐1c, 0·768 for HNA‐3a, 0·232 for HNA‐3b, 0·882 for HNA‐4a, 0·118 for HNA‐4b, 0·736 for HNA‐5a and 0·264 for HNA‐5b. Conclusion A multiplex Luminex bead assay for the simultaneous detection of HNA‐1, HNA‐3, HNA‐4 and HNA‐5 alleles is described that enables rapid typing of donors to support HNA alloimmunized patients who require HNA‐compatible blood products.
- 9 February 2013
- Published by Wiley in Vox Sanguinis
- Vol. 105 (1) , 65-72
Determination of human neutrophil antigen‐1, ‐3, ‐4 and ‐5 allele frequencies in English Caucasoid blood donors using a multiplex fluorescent DNA‐based assay
Background and Objectives A number of DNA‐based methods to genotype the alleles coding for HNA have been described, but all require the separate amplification and analysis of each allele. The aim was to develop a DNA‐based method for simultaneous detection of HNA‐1, HNA‐3, HNA‐4 and HNA‐5 alleles. Materials and Methods An allele‐specific primer extension method was used in combination with magnetic beads from Luminex technology. PCR–sequence‐specific primers (SSP) was used to resolve the presence of the HNA‐1b allele in samples assigned by the Luminex bead assay as HNA‐1a/‐1b/‐1c or HNA‐1b/‐1c. HNA allele frequencies were determined in a panel of 140 randomly selected English Caucasoid blood donors. Results HNA allelic types were compared with historical results, and 100% concordance was found. Only eight of the 97 samples used in the validation required additional testing by PCR–SSP. Allele frequencies were determined in the blood donor population as follows: 0·318 for HNA‐1a, 0·668 for HNA‐1b, 0·014 for HNA‐1c, 0·768 for HNA‐3a, 0·232 for HNA‐3b, 0·882 for HNA‐4a, 0·118 for HNA‐4b, 0·736 for HNA‐5a and 0·264 for HNA‐5b. Conclusion A multiplex Luminex bead assay for the simultaneous detection of HNA‐1, HNA‐3, HNA‐4 and HNA‐5 alleles is described that enables rapid typing of donors to support HNA alloimmunized patients who require HNA‐compatible blood products.
- 8 July 2011
- Published by Wiley in Tissue Antigens
- Vol. 78 (3) , 171-177
Simultaneous detection of HFE C282Y, H63D and S65C mutations associated with type 1 haemochromatosis using a multiplex luminex bead assay
Type 1 hereditary haemochromatosis (HH) is a common genetic disorder in Caucasoids resulting from mutations in the HFE gene. Routine diagnostic testing for type 1 HH involves genotyping for two of these described HFE mutations, C282Y and H63D. In some cases typing of a third mutation, S65C is also performed. Several techniques have been reported for HFE genotyping and these include polymerase chain reaction (PCR)‐sequence‐specific primers (SSP), PCR‐restriction fragment length polymorphism (RFLP), PCR‐sequence‐specific oligonucleotide probe (SSOP), real‐time PCR followed by melting curve analysis and TaqMan assay. The aim of this study was to develop an alternative method to both conventional PCR and real‐time PCR/TaqMan assay to detect all three HFE mutations in a single assay using Luminex technology. DNA controls of known genotypes (n = 109) were used to evaluate this approach. These controls were selected to represent the three possible genotypes (wild type, mutant, heterozygous) for each mutation. Subsequently, blind DNA samples (n = 100) were used to validate this method. This new assay was then compared with current techniques (in‐house PCR‐SSP and TaqMan assay). Comparison of genotypes obtained with the Luminex method with those previously reported by both in‐house PCR‐SSP and TaqMan assay showed 100% concordance for both DNA controls and blind DNA samples and no discrepancies were observed. Allelic frequency for C282Y, H63D and S65C mutations were 22%, 16% and 2%, respectively. We report here a high‐throughput, accurate and robust multiplex luminex bead assay for routine clinical testing of C282Y, H63D and S65C mutations in the HFE gene.
- 8 July 2011
- Published by Wiley in Tissue Antigens
- Vol. 78 (3) , 171-177
Simultaneous detection of HFE C282Y, H63D and S65C mutations associated with type 1 haemochromatosis using a multiplex luminex bead assay
Type 1 hereditary haemochromatosis (HH) is a common genetic disorder in Caucasoids resulting from mutations in the HFE gene. Routine diagnostic testing for type 1 HH involves genotyping for two of these described HFE mutations, C282Y and H63D. In some cases typing of a third mutation, S65C is also performed. Several techniques have been reported for HFE genotyping and these include polymerase chain reaction (PCR)‐sequence‐specific primers (SSP), PCR‐restriction fragment length polymorphism (RFLP), PCR‐sequence‐specific oligonucleotide probe (SSOP), real‐time PCR followed by melting curve analysis and TaqMan assay. The aim of this study was to develop an alternative method to both conventional PCR and real‐time PCR/TaqMan assay to detect all three HFE mutations in a single assay using Luminex technology. DNA controls of known genotypes (n = 109) were used to evaluate this approach. These controls were selected to represent the three possible genotypes (wild type, mutant, heterozygous) for each mutation. Subsequently, blind DNA samples (n = 100) were used to validate this method. This new assay was then compared with current techniques (in‐house PCR‐SSP and TaqMan assay). Comparison of genotypes obtained with the Luminex method with those previously reported by both in‐house PCR‐SSP and TaqMan assay showed 100% concordance for both DNA controls and blind DNA samples and no discrepancies were observed. Allelic frequency for C282Y, H63D and S65C mutations were 22%, 16% and 2%, respectively. We report here a high‐throughput, accurate and robust multiplex luminex bead assay for routine clinical testing of C282Y, H63D and S65C mutations in the HFE gene.
- 16 December 2010
- Published by Wiley in Transfusion
- Vol. 51 (6) , 1261-1270
Detection of human platelet antigen-1a alloantibodies in cases of fetomaternal alloimmune thrombocytopenia using recombinant β3 integrin fragments coupled to fluorescently labeled beads
BACKGROUND: Testing for alloantibodies against human platelet antigens (HPAs) is essential for the clinical diagnosis of fetomaternal alloimmune thrombocytopenia (FMAIT), posttransfusion purpura, and platelet (PLT) refractoriness. Most of the methods currently used for HPA alloantibody detection rely on the availability of panels of HPA-typed PLTs and some rely on validated monoclonal antibodies (MoAbs) against the PLT glycoproteins. Recombinant beta 3 integrins displaying the HPA-1a (rHPA-1a) or HPA-1b (rHPA-1b) epitopes have been produced as an alternative source of antigen. The suitability of these integrin fragments was evaluated for the development of an HPA-1a alloantibody screening assay, using Luminex xMAP technology. STUDY DESIGN AND METHODS: A 3-plex bead assay was developed by coupling biotinylated rHPA-1a, rHPA-1b, and recombinant glycoprotein VI to LumAvidin microspheres. Forty patient samples referred for FMAIT diagnostic testing, which were previously screened by the MoAb-specific immobilization of PLT antigens (MAIPA) assay, were used to assess the assay. RESULTS: The rHPA-1a- and rHPA-1b-coupled beads were able to detect HPA-1a and HPA-1b alloantibodies in all patient samples tested that were previously confirmed to contain HPA-1-specific antibodies. Furthermore, HLA Class I antibodies did not cross-react with the coupled beads. CONCLUSION: The 3-plex bead assay can be used to detect HPA-1a antibodies with sufficient specificity and sensitivity for use in the clinical setting of FMAIT. The development of other recombinant integrin fragments with the use of Luminex xMAP technology may assist in providing more rapid HPA antibody detection, enabling prompt diagnosis of alloimmune PLT disorders.
- 16 December 2010
- Published by Wiley in Transfusion
- Vol. 51 (6) , 1261-1270
Detection of human platelet antigen-1a alloantibodies in cases of fetomaternal alloimmune thrombocytopenia using recombinant β3 integrin fragments coupled to fluorescently labeled beads
BACKGROUND: Testing for alloantibodies against human platelet antigens (HPAs) is essential for the clinical diagnosis of fetomaternal alloimmune thrombocytopenia (FMAIT), posttransfusion purpura, and platelet (PLT) refractoriness. Most of the methods currently used for HPA alloantibody detection rely on the availability of panels of HPA-typed PLTs and some rely on validated monoclonal antibodies (MoAbs) against the PLT glycoproteins. Recombinant beta 3 integrins displaying the HPA-1a (rHPA-1a) or HPA-1b (rHPA-1b) epitopes have been produced as an alternative source of antigen. The suitability of these integrin fragments was evaluated for the development of an HPA-1a alloantibody screening assay, using Luminex xMAP technology. STUDY DESIGN AND METHODS: A 3-plex bead assay was developed by coupling biotinylated rHPA-1a, rHPA-1b, and recombinant glycoprotein VI to LumAvidin microspheres. Forty patient samples referred for FMAIT diagnostic testing, which were previously screened by the MoAb-specific immobilization of PLT antigens (MAIPA) assay, were used to assess the assay. RESULTS: The rHPA-1a- and rHPA-1b-coupled beads were able to detect HPA-1a and HPA-1b alloantibodies in all patient samples tested that were previously confirmed to contain HPA-1-specific antibodies. Furthermore, HLA Class I antibodies did not cross-react with the coupled beads. CONCLUSION: The 3-plex bead assay can be used to detect HPA-1a antibodies with sufficient specificity and sensitivity for use in the clinical setting of FMAIT. The development of other recombinant integrin fragments with the use of Luminex xMAP technology may assist in providing more rapid HPA antibody detection, enabling prompt diagnosis of alloimmune PLT disorders.
- 1 December 2000
- Published by Wiley in Transfusion Medicine
- Vol. 10 (4) , 328-329
On investigation of markers that may influence alloantibody responses to HPA-1a
- 1 December 2000
- Published by Wiley in Transfusion Medicine
- Vol. 10 (4) , 328-329
On investigation of markers that may influence alloantibody responses to HPA-1a